Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

Area of Science:

• Oncology
• Clinical Trials Methodology
• Biostatistics

Background:

• Individual participant data (IPD) meta-analysis is a robust method for evidence synthesis.
• Its application is expanding from clinical management to clarifying trial methodologies, particularly endpoint selection.
• The Aide et Recherche en Cancérologie Digestive (ARCAD) database is a key resource for IPD meta-analysis in oncology.

Purpose of the Study:

• To review the findings of the ARCAD project regarding endpoint selection in metastatic colorectal cancer.
• To examine the implications of these findings for future cancer trial design.
• To highlight the value of IPD meta-analysis for methodological research in oncology.

Main Methods:

• Utilized the ARCAD Metastatic Colorectal Cancer Database, containing IPD from over 38,000 patients across 46 studies.
• Conducted meta-analysis of individual participant data to evaluate endpoint validity and clinical response metrics.
• Reviewed existing literature and ARCAD project findings on endpoint selection and prognostic markers.

Main Results:

• Progression-free survival (PFS) is not a valid surrogate endpoint for overall survival in first-line metastatic colorectal cancer treatment.
• PFS remains a common endpoint in first-line trials for metastatic colorectal cancer and other solid tumors.
• Substantial PFS improvements are necessary to indicate clinically meaningful benefits.

Conclusions:

• Recommends an oncology research model focused on identifying highly effective treatments in well-defined patient populations.
• Emphasizes the importance of IPD meta-analysis for methodological studies and advancing clinical cancer research.
• Suggests IPD meta-analysis serves as a benchmark for expanding methodological approaches in cancer research.